Transformation post-Zubsolv sale led to one-time costs and a focus on R&D and AmorphOX platform partnerships. Financials showed negative cash flow and increased OpEx due to settlements and legal fees, but key pipeline projects advanced and partnering efforts intensified.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.